344 related articles for article (PubMed ID: 19349540)
21. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28.
Minami H; Sai K; Saeki M; Saito Y; Ozawa S; Suzuki K; Kaniwa N; Sawada J; Hamaguchi T; Yamamoto N; Shirao K; Yamada Y; Ohmatsu H; Kubota K; Yoshida T; Ohtsu A; Saijo N
Pharmacogenet Genomics; 2007 Jul; 17(7):497-504. PubMed ID: 17558305
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer.
Canal P; Gay C; Dezeuze A; Douillard JY; Bugat R; Brunet R; Adenis A; Herait P; Lokiec F; Mathieu-Boue A
J Clin Oncol; 1996 Oct; 14(10):2688-95. PubMed ID: 8874328
[TBL] [Abstract][Full Text] [Related]
23. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.
Iyer L; Das S; Janisch L; Wen M; Ramírez J; Karrison T; Fleming GF; Vokes EE; Schilsky RL; Ratain MJ
Pharmacogenomics J; 2002; 2(1):43-7. PubMed ID: 11990381
[TBL] [Abstract][Full Text] [Related]
24. Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRI.
Lee LS; Seng KY; Wang LZ; Yong WP; Hee KH; Soh TI; Wong A; Cheong PF; Soong R; Sapari NS; Soo R; Fan L; Lee SC; Goh BC
PLoS One; 2016; 11(1):e0147681. PubMed ID: 26808671
[TBL] [Abstract][Full Text] [Related]
25. Pharmacogenetics and irinotecan therapy.
Hahn KK; Wolff JJ; Kolesar JM
Am J Health Syst Pharm; 2006 Nov; 63(22):2211-7. PubMed ID: 17090741
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity.
Di Paolo A; Bocci G; Polillo M; Del Re M; Di Desidero T; Lastella M; Danesi R
Curr Drug Metab; 2011 Dec; 12(10):932-43. PubMed ID: 21787264
[TBL] [Abstract][Full Text] [Related]
27. Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1.
Sakaguchi S; Garcia-Bournissen F; Kim R; Schwarz UI; Nathan PC; Ito S
Arch Dis Child; 2009 Dec; 94(12):981-2. PubMed ID: 19608554
[TBL] [Abstract][Full Text] [Related]
28. Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38.
Mathijssen RH; Verweij J; Loos WJ; de Bruijn P; Nooter K; Sparreboom A
Br J Cancer; 2002 Jul; 87(2):144-50. PubMed ID: 12107833
[TBL] [Abstract][Full Text] [Related]
29. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
Soepenberg O; Dumez H; Verweij J; de Jong FA; de Jonge MJ; Thomas J; Eskens FA; van Schaik RH; Selleslach J; Ter Steeg J; Lefebvre P; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
Clin Cancer Res; 2005 Feb; 11(4):1504-11. PubMed ID: 15746053
[TBL] [Abstract][Full Text] [Related]
30. [Interest of UGT1A1 genotyping within digestive cancers treatment by irinotecan].
Boyer JC; Etienne-Grimaldi MC; Thomas F; Quaranta S; Picard N; Loriot MA; Poncet D; Gagnieu MC; Ged C; Broly F; Le Morvan V; Bouquié R; Gaub MP; Philibert L; Ghiringhelli F; Le Guellec C
Bull Cancer; 2014 Jun; 101(6):533-53. PubMed ID: 24977443
[TBL] [Abstract][Full Text] [Related]
31. Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy.
Inoue K; Sonobe M; Kawamura Y; Etoh T; Takagi M; Matsumura T; Kikuyama M; Kimura M; Minami S; Utsuki H; Yamazaki T; Suzuki T; Tsuji D; Hayashi H; Itoh K
Tohoku J Exp Med; 2013 Feb; 229(2):107-14. PubMed ID: 23303296
[TBL] [Abstract][Full Text] [Related]
32. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
Prados MD; Yung WK; Jaeckle KA; Robins HI; Mehta MP; Fine HA; Wen PY; Cloughesy TF; Chang SM; Nicholas MK; Schiff D; Greenberg HS; Junck L; Fink KL; Hess KR; Kuhn J;
Neuro Oncol; 2004 Jan; 6(1):44-54. PubMed ID: 14769140
[TBL] [Abstract][Full Text] [Related]
33. Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy.
Takane H; Kawamoto K; Sasaki T; Moriki K; Moriki K; Kitano H; Higuchi S; Otsubo K; Ieiri I
Cancer Chemother Pharmacol; 2009 May; 63(6):1165-9. PubMed ID: 18998132
[TBL] [Abstract][Full Text] [Related]
34. A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.
Pitot HC; Adjei AA; Reid JM; Sloan JA; Atherton PJ; Rubin J; Alberts SR; Duncan BA; Denis L; Schaaf LJ; Yin D; Sharma A; McGovren P; Miller LL; Erlichman C
Cancer Chemother Pharmacol; 2006 Aug; 58(2):165-72. PubMed ID: 16328416
[TBL] [Abstract][Full Text] [Related]
35. Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy.
Atasilp C; Chansriwong P; Sirachainan E; Reungwetwattana T; Sirilerttrakul S; Chamnanphon M; Puangpetch A; Sukasem C
Sci Rep; 2020 Aug; 10(1):13486. PubMed ID: 32778670
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients.
Rouits E; Charasson V; Pétain A; Boisdron-Celle M; Delord JP; Fonck M; Laurand A; Poirier AL; Morel A; Chatelut E; Robert J; Gamelin E
Br J Cancer; 2008 Oct; 99(8):1239-45. PubMed ID: 18797458
[TBL] [Abstract][Full Text] [Related]
37. Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.
Rothenberg ML; Kuhn JG; Schaaf LJ; Rodriguez GI; Eckhardt SG; Villalona-Calero MA; Rinaldi DA; Hammond LA; Hodges S; Sharma A; Elfring GL; Petit RG; Locker PK; Miller LL; von Hoff DD
Ann Oncol; 2001 Nov; 12(11):1631-41. PubMed ID: 11822765
[TBL] [Abstract][Full Text] [Related]
38. An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients.
Ichikawa W; Uehara K; Minamimura K; Tanaka C; Takii Y; Miyauchi H; Sadahiro S; Fujita K; Moriwaki T; Nakamura M; Takahashi T; Tsuji A; Shinozaki K; Morita S; Ando Y; Okutani Y; Sugihara M; Sugiyama T; Ohashi Y; Sakata Y
Br J Cancer; 2015 May; 112(10):1709-16. PubMed ID: 25880011
[TBL] [Abstract][Full Text] [Related]
39. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.
Araki K; Fujita K; Ando Y; Nagashima F; Yamamoto W; Endo H; Miya T; Kodama K; Narabayashi M; Sasaki Y
Cancer Sci; 2006 Nov; 97(11):1255-9. PubMed ID: 16965601
[TBL] [Abstract][Full Text] [Related]
40. Virtual Clinical Studies to Examine the Probability Distribution of the AUC at Target Tissues Using Physiologically-Based Pharmacokinetic Modeling: Application to Analyses of the Effect of Genetic Polymorphism of Enzymes and Transporters on Irinotecan Induced Side Effects.
Toshimoto K; Tomaru A; Hosokawa M; Sugiyama Y
Pharm Res; 2017 Aug; 34(8):1584-1600. PubMed ID: 28397089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]